Previous 10 | Next 10 |
Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference PR Newswire SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving...
Heron Therapeutics, Inc. (HRTX) Q3 2022 Earnings Conference Call November 08, 2022, 04:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - CEO and Chairman John Poyhonen - President and Chief Commercial Officer Conference Call Participa...
Heron Therapeutics press release ( NASDAQ: HRTX ): Q3 GAAP EPS of -$0.38 in-line. Revenue of $26.56M (+14.3% Y/Y) misses by $0.4M . Heron currently expects FY 2022 net product sales for the oncology care franchise of $93M to $95M, unchanged from prior outlook. ...
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates PR Newswire - APONVIE ™ approval by FDA, U.S. launch planned for Q1 2023 – - ZYNRELEF ® ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful. However, everyone must realize that...
Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 PR Newswire SAN DIEGO , Nov. 1, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the...
Summary Exparel continues to face headwinds in the near term but should continue to grow in the following years. Zilretta has not done well since last year's acquisition, but there are objective issues that Pacira is working to address and growth should resume in the following qua...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks have always fascinated investors. That’s because higher-risk, lower-priced penny stocks to buy can be portfolio game-changers. While it’s never a good idea to go overweight on penny stocks, invest...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time. Similarly, biotech stocks can ...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...